The Effect of a Natural Extract on Glucose Fluxes After Consumption of a Wheat Product

October 25, 2016 updated by: Unilever R&D
This study is to quantify the effect of a natural fruit extract added to a wheat product on the time needed to absorb 50% of the apparent total of available exogenous carbohydrate (RaE * Time). In addition the different glucose fluxes will be quantified (RaE, EGP and GCR)

Study Overview

Study Type

Interventional

Enrollment (Actual)

12

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Hanzeplein 1
      • Groningen, Hanzeplein 1, Netherlands, 9713 GZ
        • QPS

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 50 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Healthy Caucasian male.
  • Body mass index (BMI) ≥ 18.0 and ≤ 25.0 kg/m2.
  • Apparently healthy: no medical conditions which might affect the study measurements including diabetes type 1 and type 2, gastrointestinal dysfunction, gastrointestinal surgery and inflammatory diseases.
  • Fasting blood glucose value of volunteer is ≥ 3.4 and ≤ 6.1 mmol/liter (i.e. 62- 110 mg/dl) at screening.
  • HbA1c ≤ 6.5 % (48 mmol/mol).

Exclusion Criteria:

  • Use of antibiotics within 3 months before Day 1; use of any other medication except paracetamol within 14 days before Day 1.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: A wheat product
A wheat product (containing 2% 13C-universally-labeled wheat) with natural fruit extract added.
Placebo Comparator: Control
A wheat product (containing 2% 13C-universally-labeled wheat) without natural fruit extract added.
Other: Glucose solution
A solution of 50g glucose of which 2% 13C-universally-labeled glucose (2%) and unlabeled glucose (98%) in 250 mL water.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
13C (13 carbon) and D-[6,6-2H2] glucose
Time Frame: 0-6 hours
0-6 hours

Secondary Outcome Measures

Outcome Measure
Time Frame
Total blood glucose (BG)
Time Frame: 0-2 hours and 0-4 hours
0-2 hours and 0-4 hours
Insulin
Time Frame: 0-2 hours and 0-4 hours
0-2 hours and 0-4 hours
Endogenous glucose production (EGP)
Time Frame: 0-2 hours and 0-4 hours
0-2 hours and 0-4 hours
Glucose clearance rate (GCR)
Time Frame: 0-2 hours and 0-4 hours
0-2 hours and 0-4 hours
13C Metabolites of glucose (metabolomics)
Time Frame: 0-2 hours and 0-4 hours
0-2 hours and 0-4 hours
12C Metabolites of glucose (metabolomics)
Time Frame: 0-2 hours and 0-4 hours
0-2 hours and 0-4 hours
Postprandial hormones (Gastric inhibitory polypeptide, glucagon-like peptide-1 and Glucagon)
Time Frame: 0-2 hours and 0-4 hours
0-2 hours and 0-4 hours
Selected anti-oxidants (vitamin E (alpha-tocopherol), lycopene, retinol, alpha-carotene and beta-carotene)
Time Frame: -5, 60, 120, 180, 240 and 300 minutes
-5, 60, 120, 180, 240 and 300 minutes
Haematocrit
Time Frame: -5, 60, 120, 180, 240 and 300 minutes
-5, 60, 120, 180, 240 and 300 minutes
Concentration of key active in extract
Time Frame: -5, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300 and 360 minutes
-5, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300 and 360 minutes
13CO2 in breath
Time Frame: 30, 30, 60, 90,120, 150, 180 and every 30 minutes up to 6 hours
30, 30, 60, 90,120, 150, 180 and every 30 minutes up to 6 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Tjeerd Mensinga, MD, PhD, QPS Netherlands

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2016

Primary Completion (Actual)

February 1, 2016

Study Completion (Actual)

February 1, 2016

Study Registration Dates

First Submitted

January 20, 2016

First Submitted That Met QC Criteria

January 20, 2016

First Posted (Estimate)

January 25, 2016

Study Record Updates

Last Update Posted (Estimate)

October 26, 2016

Last Update Submitted That Met QC Criteria

October 25, 2016

Last Verified

October 1, 2016

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • FDS-NAA-1650

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Placebo

Subscribe